(NASDAQ: EYPT) Eyepoint Pharmaceuticals's forecast annual revenue growth rate of 28.62% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Eyepoint Pharmaceuticals's revenue in 2025 is $43,273,000.On average, 4 Wall Street analysts forecast EYPT's revenue for 2025 to be $959,109,846, with the lowest EYPT revenue forecast at $285,911,642, and the highest EYPT revenue forecast at $1,687,978,346. On average, 3 Wall Street analysts forecast EYPT's revenue for 2026 to be $241,925,235, with the lowest EYPT revenue forecast at $178,694,776, and the highest EYPT revenue forecast at $285,911,642.
In 2027, EYPT is forecast to generate $8,477,348,902 in revenue, with the lowest revenue forecast at $3,704,480,164 and the highest revenue forecast at $13,250,217,640.